This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
7/30/2026
Kevin Boss
Head of Investor Relations
Good afternoon or good morning everyone and welcome to our half year 2026 investor webcast. My name is Kevin Boss and I'm responsible for investor relations at IDORSIA. Today, rather than simply reviewing what happened during the first six months of the year, we want to focus on what will drive the next phase of growth and value creation at IDORSIA. Joining me on the call, we have Jean-Paul Clozel, chairman and interim CEO, Benjamin Limal, head of Europe and international markets, Charlie Jacobovitz, President of Eidosia US, Martine Clozel, Chief Scientific Officer and Head of Research, Dominique Le Terrier, Global Commercial Strategy and New Product Planning, Amer Joseph, Chief Medical Officer and Head of Global Clinical Development, and Arno Groenewoud, our Chief Financial Officer. Each of them will take you through the progress being made across the business before joining the Q&A session.
Arno Groenewoud
Chief Financial Officer
Next slide.
Kevin Boss
Head of Investor Relations
As always, today's presentation contains forward-looking statements that involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied by such statements. With that, let me hand over to Jean-Paul. Next slide.
You're reading a preview of the IDRSF Q2 2026 earnings call.
Free account.
Disclaimer